Plain-English translation of NCT07114939 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging scan called [18F]FTT PET/CT, which uses a radioactive dye to help doctors see pancreatic neuroendocrine tumors more clearly. The scan is designed to highlight specific proteins in tumor cells that may help predict which patients could benefit from a type of cancer drug called PARP inhibitors. By studying how tumors light up on this new scan, researchers hope to learn more about these rare cancers and find better ways to treat them.
Pancreatic neuroendocrine tumors are rare and hard to treat, and doctors don't yet have good ways to identify which patients will respond to PARP inhibitor drugs. This study exists to see if the new imaging scan can help doctors understand these tumors better and predict who might benefit from this type of treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive an injection of the radioactive dye through an IV, then lie still in a PET/CT scanner for about 60 minutes while it takes images of your body. A second set of images may be taken up to 90 minutes after the injection. Researchers will also review tumor tissue samples that were already collected as part of your regular medical care or a tissue bank to study the proteins the new scan is designed to detect.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States